Nordion Inc., a health science company, provides various products and services used for the prevention, diagnosis, and treatment of diseases worldwide. It is involved in the processing, packaging, and delivery of medical isotopes used in the diagnosis and treatment of diseases, such as cardiology, oncology, and neurology. The company primarily offers Molybdenum-99, which decays into Technetium-99, utilized in nuclear medical procedures; processes and sells other reactor isotopes, including Xe-133 used in lung scans and I-125 used to treat prostate cancer, as well as I-131 used to treat hyperthyroidism, thyroid cancer, and non-Hodgkin’s lymphoma; and manufactures and processes cyclotron isotopes. It also supplies targeted therapies for various cancers, which focus on targeting the disease from within the body with a higher concentration of radiation directed to the tumor. Its primary targeted therapies product includes TheraSphere, a treatment for inoperable primary and metastatic liver cancer, as well as offers radiopharmaceutical and medical imaging services; and contract manufacturing services for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development. In addition, the company provides gamma sterilization technologies used to sterilize disposable medical devices and supplies, such as surgeon's gloves, syringes, sutures, and catheters, as well as pharmaceuticals; and used for the treatment of food and consumer products. It produces and installs Cobalt-60 irradiation sources; and designs, constructs, installs, and maintains commercial gamma sterilization systems. Nordion Inc. offers its products and services to pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics, and research laboratories. The company was formerly known as MDS Inc. and changed its name to Nordion Inc. in November 2010. Nordion Inc. was founded in 1946 and is headquartered in Ottawa, Canada.